Tricot G - Search Results

1

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase.

Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. Gu Z, et al. Among authors: tricot g. J Hematol Oncol. 2017 Jan 13;10(1):17. doi: 10.1186/s13045-017-0392-4. J Hematol Oncol. 2017. PMID: 28086949 Free PMC article.

2

NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F. Zhou W, et al. Among authors: tricot g. Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001. Cancer Cell. 2013. PMID: 23328480 Free PMC article.

3

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.

Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. Yang Y, et al. Among authors: tricot g. Oncotarget. 2014 Dec 15;5(23):11986-97. doi: 10.18632/oncotarget.2388. Oncotarget. 2014. PMID: 25230277 Free PMC article.

4

Nek2 is a novel regulator of B cell development and immunological response.

Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G, Zhan F. Gu Z, et al. Among authors: tricot g. Biomed Res Int. 2014;2014:621082. doi: 10.1155/2014/621082. Epub 2014 Nov 17. Biomed Res Int. 2014. PMID: 25485281 Free PMC article.

5

Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.

Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F. Franqui-Machin R, et al. Among authors: tricot g. J Clin Invest. 2018 Jul 2;128(7):2877-2893. doi: 10.1172/JCI98765. Epub 2018 Jun 4. J Clin Invest. 2018. PMID: 29863498 Free PMC article.

6

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F. Hao M, et al. Among authors: tricot g. Leukemia. 2017 Jul;31(7):1648-1650. doi: 10.1038/leu.2017.115. Epub 2017 Apr 12. Leukemia. 2017. PMID: 28400617 Free PMC article. No abstract available.

7

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F. Shi L, et al. Among authors: tricot g. Oncotarget. 2010 May;1(1):22-33. doi: 10.18632/oncotarget.105. Oncotarget. 2010. PMID: 20930946 Free PMC article.

8

RARα2 expression confers myeloma stem cell features.

Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F, Tricot G. Yang Y, et al. Among authors: tricot g. Blood. 2013 Aug 22;122(8):1437-47. doi: 10.1182/blood-2013-02-482919. Epub 2013 Jul 11. Blood. 2013. PMID: 23847194 Free PMC article.

9

Inhibition of Nek2 by small molecules affects proteasome activity.

Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ. Meng L, et al. Among authors: tricot g. Biomed Res Int. 2014;2014:273180. doi: 10.1155/2014/273180. Epub 2014 Sep 17. Biomed Res Int. 2014. PMID: 25313354 Free PMC article.

10

Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.

Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Yang Y, et al. Among authors: tricot g. Cancer Res. 2015 Feb 1;75(3):594-604. doi: 10.1158/0008-5472.CAN-14-2362. Epub 2015 Jan 14. Cancer Res. 2015. PMID: 25589346 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

484 results

Search Page